Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and ...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA ...
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Accessibility Tools